A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.
Generic drug giant Actavis Global has reached a settlement with AstraZeneca in a long-running patent dispute over blockbuster cholesterol medicine Crestor that wound its way to the High Court.
A judge has vacated a trial scheduled to start next week in Melbourne between the ACCC and NIB Health Funds over claims the health insurer violated consumer protection laws by making changes to its plans without first notifying members.
In a major loss for the ACCC, the Full Federal Court on Friday tossed the competition regulator’s challenge to a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
Troubled sandalwood oil producer Quintis has been hit with a third class action over the company’s lost contract with Nestle unit Galderma, and this time its auditor, Ernst & Young, has been named as a co-defendant.
The ACCC will face a test of its ability to win misuse of market power cases when a long-awaited judgment is handed down this week in the regulator’s appeal of a ruling dismissing its case alleging Pfizer misused its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
The union representing Dorevitch Pathology workers has settled a Fair Work case against the lab giant over a lockout notice the company sent to staff ahead of last year’s planned strike over pay.
Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to “tens of millions of dollars” in losses.
Telecom giant Optus has come up short in a Federal Court challenge to trademark registration for health services company Optum, with a judge saying the two company’s marks — despite the difference of just one letter — were distinct enough.